Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HACOL-ACS: Bempedoic acid to achieve LDL-cholesterol targets after acute myocardial infarction
2024-513703-13-00Phase 3Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bempedoic acid in myocardial infarction (MI), coronary arteriosclerosis and hypercholesterolemia, sponsored by Medizinische Hochschule Hannover. Primary endpoint: Primary: proportion achieving ESC LDL-C target with triple therapy at 8 weeks. Started Nov 2024; status: completed.
02
Drugs
bempedoic acid
03
Conditions
myocardial infarction (MI)coronary arteriosclerosishypercholesterolemia
Beyond the preview
Go deeper on 2024-513703-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513703-13-00.